ArticleBlood advances2024

Dave H, Terpilowski M, Mai M, et al. Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma. Blood Adv. 2022;6(2):473-485.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.